BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

981 related articles for article (PubMed ID: 28710224)

  • 1. Assessing the effectiveness of a 3-month day-and-night home closed-loop control combined with pump suspend feature compared with sensor-augmented pump therapy in youths and adults with suboptimally controlled type 1 diabetes: a randomised parallel study protocol.
    Bally L; Thabit H; Tauschmann M; Allen JM; Hartnell S; Wilinska ME; Exall J; Huegel V; Sibayan J; Borgman S; Cheng P; Blackburn M; Lawton J; Elleri D; Leelarathna L; Acerini CL; Campbell F; Shah VN; Criego A; Evans ML; Dunger DB; Kollman C; Bergenstal RM; Hovorka R
    BMJ Open; 2017 Jul; 7(7):e016738. PubMed ID: 28710224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial.
    Tauschmann M; Thabit H; Bally L; Allen JM; Hartnell S; Wilinska ME; Ruan Y; Sibayan J; Kollman C; Cheng P; Beck RW; Acerini CL; Evans ML; Dunger DB; Elleri D; Campbell F; Bergenstal RM; Criego A; Shah VN; Leelarathna L; Hovorka R;
    Lancet; 2018 Oct; 392(10155):1321-1329. PubMed ID: 30292578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing the efficacy, safety and utility of 6-month day-and-night automated closed-loop insulin delivery under free-living conditions compared with insulin pump therapy in children and adolescents with type 1 diabetes: an open-label, multicentre, multinational, single-period, randomised, parallel group study protocol.
    Musolino G; Allen JM; Hartnell S; Wilinska ME; Tauschmann M; Boughton C; Campbell F; Denvir L; Trevelyan N; Wadwa P; DiMeglio L; Buckingham BA; Weinzimer S; Acerini CL; Hood K; Fox S; Kollman C; Sibayan J; Borgman S; Cheng P; Hovorka R
    BMJ Open; 2019 Jun; 9(6):e027856. PubMed ID: 31164368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing the effectiveness of 3 months day and night home closed-loop insulin delivery in adults with suboptimally controlled type 1 diabetes: a randomised crossover study protocol.
    Leelarathna L; Dellweg S; Mader JK; Barnard K; Benesch C; Ellmerer M; Heinemann L; Kojzar H; Thabit H; Wilinska ME; Wysocki T; Pieber TR; Arnolds S; Evans ML; Hovorka R;
    BMJ Open; 2014 Sep; 4(9):e006075. PubMed ID: 25186158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of 6 months of hybrid closed-loop insulin delivery in adults with type 1 diabetes: a randomised controlled trial protocol.
    McAuley SA; de Bock MI; Sundararajan V; Lee MH; Paldus B; Ambler GR; Bach LA; Burt MG; Cameron FJ; Clarke PM; Cohen ND; Colman PG; Davis EA; Fairchild JM; Hendrieckx C; Holmes-Walker DJ; Horsburgh JC; Jenkins AJ; Kaye J; Keech AC; King BR; Kumareswaran K; MacIsaac RJ; McCallum RW; Nicholas JA; Sims C; Speight J; Stranks SN; Trawley S; Ward GM; Vogrin S; Jones TW; O'Neal DN
    BMJ Open; 2018 Jun; 8(6):e020274. PubMed ID: 29886443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Day-and-night glycaemic control with closed-loop insulin delivery versus conventional insulin pump therapy in free-living adults with well controlled type 1 diabetes: an open-label, randomised, crossover study.
    Bally L; Thabit H; Kojzar H; Mader JK; Qerimi-Hyseni J; Hartnell S; Tauschmann M; Allen JM; Wilinska ME; Pieber TR; Evans ML; Hovorka R
    Lancet Diabetes Endocrinol; 2017 Apr; 5(4):261-270. PubMed ID: 28094136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing the effect of closed-loop insulin delivery from onset of type 1 diabetes in youth on residual beta-cell function compared to standard insulin therapy (CLOuD study): a randomised parallel study protocol.
    Boughton C; Allen JM; Tauschmann M; Hartnell S; Wilinska ME; Musolino G; Acerini CL; Dunger PD; Campbell F; Ghatak A; Randell T; Besser R; Trevelyan N; Elleri D; Northam E; Hood K; Scott E; Lawton J; Roze S; Sibayan J; Kollman C; Cohen N; Todd J; Hovorka R;
    BMJ Open; 2020 Mar; 10(3):e033500. PubMed ID: 32169925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing the efficacy, safety and utility of closed-loop insulin delivery compared with sensor-augmented pump therapy in very young children with type 1 diabetes (KidsAP02 study): an open-label, multicentre, multinational, randomised cross-over study protocol.
    Fuchs J; Allen JM; Boughton CK; Wilinska ME; Thankamony A; de Beaufort C; Campbell F; Yong J; Froehlich-Reiterer E; Mader JK; Hofer SE; Kapellen TM; Rami-Merhar B; Tauschmann M; Hood K; Kimbell B; Lawton J; Roze S; Sibayan J; Cohen N; Hovorka R;
    BMJ Open; 2021 Feb; 11(2):e042790. PubMed ID: 33579766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of the predictive low glucose management system in the prevention of hypoglycaemia: protocol for randomised controlled home trial to evaluate the Suspend before low function.
    Abraham MB; Nicholas JA; Ly TT; Roby HC; Paramalingam N; Fairchild J; King BR; Ambler GR; Cameron F; Davis EA; Jones TW
    BMJ Open; 2016 Apr; 6(4):e011589. PubMed ID: 27084290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unsupervised home use of an overnight closed-loop system over 3-4 weeks: a pooled analysis of randomized controlled studies in adults and adolescents with type 1 diabetes.
    Thabit H; Elleri D; Leelarathna L; Allen JM; Lubina-Solomon A; Stadler M; Walkinshaw E; Iqbal A; Choudhary P; Wilinska ME; Barnard KD; Heller SR; Amiel SA; Evans ML; Dunger DB; Hovorka R
    Diabetes Obes Metab; 2015 May; 17(5):452-8. PubMed ID: 25492378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Threshold-based insulin-pump interruption for reduction of hypoglycemia.
    Bergenstal RM; Klonoff DC; Garg SK; Bode BW; Meredith M; Slover RH; Ahmann AJ; Welsh JB; Lee SW; Kaufman FR;
    N Engl J Med; 2013 Jul; 369(3):224-32. PubMed ID: 23789889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outpatient 60-hour day-and-night glucose control with dual-hormone artificial pancreas, single-hormone artificial pancreas, or sensor-augmented pump therapy in adults with type 1 diabetes: An open-label, randomised, crossover, controlled trial.
    Haidar A; Messier V; Legault L; Ladouceur M; Rabasa-Lhoret R
    Diabetes Obes Metab; 2017 May; 19(5):713-720. PubMed ID: 28094472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Home Use of Day-and-Night Hybrid Closed-Loop Insulin Delivery in Suboptimally Controlled Adolescents With Type 1 Diabetes: A 3-Week, Free-Living, Randomized Crossover Trial.
    Tauschmann M; Allen JM; Wilinska ME; Thabit H; Acerini CL; Dunger DB; Hovorka R
    Diabetes Care; 2016 Nov; 39(11):2019-2025. PubMed ID: 27612500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Closed-loop insulin delivery in adults with type 1 diabetes in real-life conditions: a 12-week multicentre, open-label randomised controlled crossover trial.
    Benhamou PY; Franc S; Reznik Y; Thivolet C; Schaepelynck P; Renard E; Guerci B; Chaillous L; Lukas-Croisier C; Jeandidier N; Hanaire H; Borot S; Doron M; Jallon P; Xhaard I; Melki V; Meyer L; Delemer B; Guillouche M; Schoumacker-Ley L; Farret A; Raccah D; Lablanche S; Joubert M; Penfornis A; Charpentier G;
    Lancet Digit Health; 2019 May; 1(1):e17-e25. PubMed ID: 33323237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Home use of closed-loop insulin delivery for overnight glucose control in adults with type 1 diabetes: a 4-week, multicentre, randomised crossover study.
    Thabit H; Lubina-Solomon A; Stadler M; Leelarathna L; Walkinshaw E; Pernet A; Allen JM; Iqbal A; Choudhary P; Kumareswaran K; Nodale M; Nisbet C; Wilinska ME; Barnard KD; Dunger DB; Heller SR; Amiel SA; Evans ML; Hovorka R
    Lancet Diabetes Endocrinol; 2014 Sep; 2(9):701-9. PubMed ID: 24943065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of sensor-integrated pump therapy to reduce hypoglycaemia in people with Type 1 diabetes: a real-world study in the UK.
    Choudhary P; de Portu S; Arrieta A; Castañeda J; Campbell FM
    Diabet Med; 2019 Sep; 36(9):1100-1108. PubMed ID: 31134668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A cluster randomised trial, cost-effectiveness analysis and psychosocial evaluation of insulin pump therapy compared with multiple injections during flexible intensive insulin therapy for type 1 diabetes: the REPOSE Trial.
    Heller S; White D; Lee E; Lawton J; Pollard D; Waugh N; Amiel S; Barnard K; Beckwith A; Brennan A; Campbell M; Cooper C; Dimairo M; Dixon S; Elliott J; Evans M; Green F; Hackney G; Hammond P; Hallowell N; Jaap A; Kennon B; Kirkham J; Lindsay R; Mansell P; Papaioannou D; Rankin D; Royle P; Smithson WH; Taylor C
    Health Technol Assess; 2017 Apr; 21(20):1-278. PubMed ID: 28440211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Day-and-Night Hybrid Closed-Loop Insulin Delivery in Adolescents With Type 1 Diabetes: A Free-Living, Randomized Clinical Trial.
    Tauschmann M; Allen JM; Wilinska ME; Thabit H; Stewart Z; Cheng P; Kollman C; Acerini CL; Dunger DB; Hovorka R
    Diabetes Care; 2016 Jul; 39(7):1168-74. PubMed ID: 26740634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial.
    Kropff J; Del Favero S; Place J; Toffanin C; Visentin R; Monaro M; Messori M; Di Palma F; Lanzola G; Farret A; Boscari F; Galasso S; Magni P; Avogaro A; Keith-Hynes P; Kovatchev BP; Bruttomesso D; Cobelli C; DeVries JH; Renard E; Magni L;
    Lancet Diabetes Endocrinol; 2015 Dec; 3(12):939-47. PubMed ID: 26432775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of suspend-before-low insulin pump technology in hypoglycaemia-prone adults with type 1 diabetes (SMILE): an open-label randomised controlled trial.
    Bosi E; Choudhary P; de Valk HW; Lablanche S; Castañeda J; de Portu S; Da Silva J; Ré R; Vorrink-de Groot L; Shin J; Kaufman FR; Cohen O;
    Lancet Diabetes Endocrinol; 2019 Jun; 7(6):462-472. PubMed ID: 31047902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.